



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Application of:

**Xiao-Mai ZHOU**

Conf. No.: **8284**

Appln. No.: **09/580,523**

Group Art Unit: **1642**

Filed: **May 30, 2000**

Examiner: **Davis, M.**

For: **COMPOUNDS AND METHODS FOR REGULATING  
APOPTOSIS, AND METHODS OF MAKING AND SCREENING  
FOR COMPOUNDS THAT REGULATE APOPTOSIS**

**RECEIVED**

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

**JUN 04 2003**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TECH CENTER 1600/2900**

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of each of the listed documents and the corresponding Communication dated May 6, 2003, from the Foreign Patent Office, is submitted herewith,.


The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action. Therefore Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

The present Information Disclosure Statement is being filed thirty days or fewer from the Communication from a foreign patent office and a Statement Under 37 C.F.R. § 1.704(d) is attached.

**INFORMATION DISCLOSURE STATEMENT**  
**U.S. Appl. No. 09/580,523**

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



\_\_\_\_\_  
Drew Hissong  
Registration No. 44,765

**SUGHRUE MION, PLLC**  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE



**23373**

PATENT TRADEMARK OFFICE

Date: May 30, 2003



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Application of:

Xiao-Mai ZHOU

Conf. No.: 8284

Appln. No.: 09/580,523

Group Art Unit: 1642

Filed: May 30, 2000

Examiner: Davis, M.

For: **COMPOUNDS AND METHODS FOR REGULATING  
APOPTOSIS, AND METHODS OF MAKING AND SCREENING  
FOR COMPOUNDS THAT REGULATE APOPTOSIS**

#  
20  
KD  
65203

RECEIVED

STATEMENT UNDER 37 C.F.R. § 1.704(d)

JUN 04 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making a reasonable inquiry, that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

**SUGHRUE MION, PLLC**  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Drew Hissong  
Registration No. 44,765

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: May 30, 2003

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Application Number	09/580,523
Confirmation Number	8284
Filing Date	May 30, 2000
First Named Inventor	Xiao-Mai ZHOU
Art Unit	1642
Examiner Name	Davis, M.
Attorney Docket Number	A7483

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Ottillie et al, <i>J. of Biol. Chem.</i> , 272(49):30866-30872 (1997)	
		Harada et al, <i>Mol. Cell</i> , 3(4):413-422 (1999)	
		Datta et al, <i>Cell</i> , 91(2):231-241 (1997)	
		Zha et al, <i>Cell</i> , 87(4):619-628 (1996)	
		Datta et al, <i>Mol. Cell</i> , 6(1):41-51 (2000)	
		Zhou et al, <i>J. of Biol. Chem.</i> , 275(32):25046-25051 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.